March 2017

Welcome to the PM Buzz with the latest headlines in precision medicine and the latest news, content and events from Diaceutics.
Latest News in Personalized and Precision Medicine

FDA’s personalized medicine leader moves to new role at liquid biopsy startup Grail read on...
Vir Biotechnology launches to cure, treat, and prevent challenging infectious diseases using latest advances in immunology read on...
IBM and Illumina partner to standardize genomic data interpretation read on...
Roche uses wearables in spinal muscle atrophy clinical trials read on...
Molecular Stethoscope completes $8.2m seed financing to advance circulating cell-free RNA liquid biopsy platform; announces research collaboration with Pfizer read on...
'Huge leap' in prostate cancer testing read on...
Angle plc selected for European CANCER-ID programme read on...
GenomeDx’s Decipher biopsy demonstrates ability to predict metastasis after radiation and androgen deprivation therapy in prostate cancer patients read on...
Circulating tumor cell analysis improves HCC diagnosis read on...
ICG100 genomic test for blood cancers to include 162 genes using less DNA read on...
bioMérieux and Banyan Biomarkers partner to develop, validate and market blood-based biomarkers for traumatic brain injury read on...
Bristol-Myers Squibb and GeneCentric Diagnostics announce exploratory biomarker research collaboration read on...
AstraZeneca delays PD-L1 data in rejig of phase 3 program read on...
Sebia signs agreement with Janssen Biotech (JNJ) to develop a multiple myeloma IVD test read on...
miRagen Therapeutics completes merger with Signal Genetics and concurrent $40.7 million equity financing read on...
MD Anderson and Guardant Health announce partnership to make comprehensive liquid biopsy part of oncology standard of care read on...
Strata Oncology announces collaboration with Epizyme to support tazemetostat clinical development read on...
Clovis Oncology and Strata Oncology announce collaboration to accelerate enrollment in rucaparib prostate cancer development program read on...
GenomeDx announces research collaboration with Astellas to identify genomic drivers of patient response to Xtandi (enzalutamide) capsules read on...
Quest Diagnostics partners with Montefiore Health System to deliver high-value, innovative laboratory services read on...
Daktari achieves milestone in its Merck HCV collaboration read on...
bioMONTR Labs announces laboratory service agreements with ViiV Healthcare read on...
Invivoscribe announces long-term collaboration to develop immuno-oncology tests with Thermo Fisher Scientific read on...
Novartis to sell Genoptix lab business to private investor group read on...
Adaptive Biotechnologies announces a collaboration with Amgen to advance development of clonoSEQ assay in acute lymphoblastic leukemia read on...
Telix Pharmaceuticals and Atlab Pharma conclude therapeutic product development agreement for prostate cancer read on...
FDA releases discussion paper on LDT regulation following stakeholder feedback read on...
Agilent Technologies expands Dako’s CE marked PD-L1 22c3 pharmDx companion diagnostics read on...
Humana issues positive coverage decision for NanoString's Prosigna breast cancer assay read on...
Hematogenix announces the recognition by Merck & Co. as one of the national reference laboratories offering PD-L1 testing for Keytruda read on...
Cynvenio and Milenia Labs enter into exclusive distribution agreement for ClearID breast cancer testing in Mexico read on...
Hope Biosciences licenses nuc-gemcitabine, a 'Trojan Horse' anti-nucleolin-gemcitabine aptamer drug conjugate against cancer read on...
FDA 510(k) clearance for the second generation Bindex point-of-care device for osteoporosis read on...
The winners and losers if Obamacare is replaced read on...
Another Opdivo setback for Bristol, this time on the combo front, widening Merck's immuno-oncology lead read on...
Merck CEO sees Keytruda in pole position in cancer race read on...
Obamacare repeal may help pharmaceutical industry, Novartis says read on...
This month in Diaceutics news

[Webinar] What are the major differences in biomarker test adoption in European countries? An analysis of PD–L1 testing in Italy and Germany read on...


     

© 2017 Diaceutics. All rights reserved.
Not interested? Unsubscribe | Update profile | Impressed? Tell-A-Friend
Diaceutics | Belfast - New York